Advertisement

Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy

Published:October 15, 2018DOI:https://doi.org/10.1016/j.jhep.2018.09.029

      Highlights

      • There was no significant difference in the early HCC recurrence rate and pattern between IFN-based and DAA therapy.
      • High AFP-L3, short recurrence-free period, and history of multiple HCC treatments were risk factors for early recurrence.
      • Eradication of HCV after curative HCC treatments could preserve liver function, regardless of antiviral therapy regimen.

      Background & Aims

      It remains controversial whether direct-acting antivirals (DAAs) accelerate the recurrence of hepatitis C-related hepatocellular carcinoma (HCC) after curative therapy. This study aimed to evaluate HCC recurrence after DAA treatment of chronic hepatitis C.

      Methods

      We enrolled patients with a history of successful radiofrequency ablation treatment for hepatitis C-related HCC who received antiviral therapy with DAAs (DAA group: 147 patients) or with interferon (IFN)-based therapy (IFN group: 156 patients). We assessed HCC recurrence rates from the initiation of antiviral therapy using the Kaplan-Meier method and evaluated risk factors for HCC recurrence by multivariate Cox proportional hazard regression analysis. The recurrence pattern was categorized as follows: intrahepatic recurrence with a single tumor <2 cm (stage 0), a single tumor or up to 3 tumors ≤3 cm (stage A), multinodular (stage B), and extrahepatic metastasis or macrovascular invasion (stage C).

      Results

      The recurrence rates at 1 and 2 years were 39% and 61% in the IFN group and 39% and 60% in the DAA group, respectively (p = 0.43). Multivariate analysis identified higher lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level, a history of multiple HCC treatments, and a shorter interval between HCC treatment and initiation of antiviral therapy as independent risk factors for HCC recurrence. HCC recurrence in stage 0, A, B, and C was found in 56 (41%), 60 (44%), 19 (14%), and 1 (0.7%) patients in the IFN group and 35 (44%), 32 (40%), 11 (14%), and 2 (2.5%) patients in the DAA group, respectively (p = 0.70).

      Conclusions

      HCC recurrence rates and patterns after initiation of antiviral therapy did not differ between patients who received IFN-based therapy and DAA therapy.

      Lay summary

      We detected no significant difference in early hepatocellular carcinoma (HCC) recurrence rates and patterns between patients who received interferon-based and direct-acting antiviral therapy after HCC treatment. High lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level, short recurrence-free period, and a history of multiple HCC treatments were independent risk factors for early HCC recurrence after the initiation of antiviral therapy.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Torre L.A.
        • Bray F.
        • Siegel R.L.
        • Ferlay J.
        • Lortet-Tieulent J.
        • Jemal A.
        Global cancer statistics, 2012.
        CA Cancer J Clin. 2015; 65: 87-108
        • Simonetti R.G.
        • Camma C.
        • Fiorello F.
        • Cottone M.
        • Rapicetta M.
        • Marino L.
        • et al.
        Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.
        Ann Intern Med. 1992; 116: 97-102
        • El-Serag H.B.
        Epidemiology of viral hepatitis and hepatocellular carcinoma.
        Gastroenterology. 2012; 142 (1264–1273 e1261)
        • Shiratori Y.
        • Shiina S.
        • Teratani T.
        • Imamura M.
        • Obi S.
        • Sato S.
        • et al.
        Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.
        Ann Intern Med. 2003; 138: 299-306
        • Mazzaferro V.
        • Romito R.
        • Schiavo M.
        • Mariani L.
        • Camerini T.
        • Bhoori S.
        • et al.
        Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
        Hepatology. 2006; 44: 1543-1554
        • Shen Y.C.
        • Hsu C.
        • Chen L.T.
        • Cheng C.C.
        • Hu F.C.
        • Cheng A.L.
        Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach.
        J Hepatol. 2010; 52: 889-894
        • Minami T.
        • Tateishi R.
        • Shiina S.
        • Nakagomi R.
        • Kondo M.
        • Fujiwara N.
        • et al.
        Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma.
        Hepatol Res. 2015; 45: E99-E107
      1. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016;65:734–740.

        • Cabibbo G.
        • Petta S.
        • Calvaruso V.
        • Cacciola I.
        • Cannavo M.R.
        • Madonia S.
        • et al.
        Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
        Aliment Pharmacol Ther. 2017; 46: 688-695
        • Conti F.
        • Buonfiglioli F.
        • Scuteri A.
        • Crespi C.
        • Bolondi L.
        • Caraceni P.
        • et al.
        Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
        J Hepatol. 2016; 65: 727-733
        • Reig M.
        • Marino Z.
        • Perello C.
        • Inarrairaegui M.
        • Ribeiro A.
        • Lens S.
        • et al.
        Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
        J Hepatol. 2016; 65: 719-726
        • Minami T.
        • Tateishi R.
        • Nakagomi R.
        • Fujiwara N.
        • Sato M.
        • Enooku K.
        • et al.
        The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.
        J Hepatol. 2016; 65: 1272-1273
        • Lencioni R.
        • Llovet J.M.
        Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
        Semin Liver Dis. 2010; 30: 52-60
        • Torzilli G.
        • Minagawa M.
        • Takayama T.
        • Inoue K.
        • Hui A.M.
        • Kubota K.
        • et al.
        Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy.
        Hepatology. 1999; 30: 889-893
        • Torres H.A.
        • Vauthey J.N.
        • Economides M.P.
        • Mahale P.
        • Kaseb A.
        Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment.
        J Hepatol. 2016; 65: 862-864
        • Zeng Q.L.
        • Li Z.Q.
        • Liang H.X.
        • Xu G.H.
        • Li C.X.
        • Zhang D.W.
        • et al.
        Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?.
        J Hepatol. 2016; 62: 1068-1069
        • Ikeda K.
        • Kawamura Y.
        • Kobayashi M.
        • Kominami Y.
        • Fujiyama S.
        • Sezaki H.
        • et al.
        Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma.
        Dig Dis Sci. 2017; 62: 2932-2942
        • Kolly P.
        • Waidmann O.
        • Vermehren J.
        • Moreno C.
        • Vogeli I.
        • Berg T.
        • et al.
        Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study.
        J Hepatol. 2017; 67: 876-878
        • Nagata H.
        • Nakagawa M.
        • Asahina Y.
        • Sato A.
        • Asano Y.
        • Tsunoda T.
        • et al.
        Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
        J Hepatol. 2017; 67: 933-939
        • Petta S.
        • Cabibbo G.
        • Barbara M.
        • Attardo S.
        • Bucci L.
        • Farinati F.
        • et al.
        Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
        Aliment Pharmacol Ther. 2017; 45: 160-168
        • Virlogeux V.
        • Pradat P.
        • Hartig-Lavie K.
        • Bailly F.
        • Maynard M.
        • Ouziel G.
        • et al.
        Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
        Liver Int. 2017; 37: 1122-1127
        • Zavaglia C.
        • Okolicsanyi S.
        • Cesarini L.
        • Mazzarelli C.
        • Pontecorvi V.
        • Ciaccio A.
        • et al.
        Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?.
        J Hepatol. 2017; 66: 236-237
        • Kushner T.
        • Dieterich D.
        • Saberi B.
        Direct-acting antiviral treatment for patients with hepatocellular carcinoma.
        Curr Opin Gastroenterol. 2018; 34: 132-139
        • Tateishi R.
        • Shiina S.
        • Yoshida H.
        • Teratani T.
        • Obi S.
        • Yamashiki N.
        • et al.
        Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
        Hepatology. 2006; 44: 1518-1527
        • Sato Y.
        • Nakata K.
        • Kato Y.
        • Shima M.
        • Ishii N.
        • Koji T.
        • et al.
        Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein.
        N Engl J Med. 1993; 328: 1802-1806
        • Taketa K.
        • Endo Y.
        • Sekiya C.
        • Tanikawa K.
        • Koji T.
        • Taga H.
        • et al.
        A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma.
        Cancer Res. 1993; 53: 5419-5423
        • Yamashiki N.
        • Yoshida H.
        • Tateishi R.
        • Shiina S.
        • Teratani T.
        • Kondo Y.
        • et al.
        Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment.
        J Gastroenterol Hepatol. 2007; 22: 2155-2160
        • Cabibbo G.
        • Petta S.
        • Barbara M.
        • Missale G.
        • Virdone R.
        • Caturelli E.
        • et al.
        A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.
        Liver Int. 2017; 37: 1157-1166
        • Cabibbo G.
        • Petta S.
        • Barbara M.
        • Attardo S.
        • Bucci L.
        • Farinati F.
        • et al.
        Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
        J Hepatol. 2017; 67: 65-71